A liquid nitrogen bank containing a suspension of stem cells. (Photo: Elena Pavlovich, via Shutterstock)California’s stem cell agency gave away $14 million this month, which could be described as less than a drop in its $3 billion bucket. But the talk at the agency’s awards meeting July 19 was not about largess. Instead it was about the lack of cash, lack of time and the need to split “babies” and “buckets.”
An illustration of stem cells used in research. (Photo: Billion Photos, via Shutterstock)California’s $3 billion stem cell research agency, which is facing its financial demise in a few short years, has formed a team of its directors to tackle transition planning and examine possible alternatives, including ones that would extend its life. The first meeting of the group of directors is tentatively scheduled for Sept. 18.
The Lorry I. Lokey stem cell research building at Stanford University, a major facility of the California Institute for Regenerative Medicine. (Photo: CIRM)California’s $3 billion stem cell research program is looking for a new president to carry the state agency through what may be the last three years of its life. The search committee of the agency’s 29-member governing board meets July 17 to discuss the matter behind closed doors.
A photo illustration of human DNA. (Photo: Shutterstock)Plans to ask California voters in 2018 to approve a $5 billion bond issue to finance the California stem cell agency have been shelved, a director of the agency said Thursday. Jeff Sheehy, a San Francisco county supervisor, said that the key backer of the proposal had informed him that no bond measure would be offered to voters before 2020, presumably at the presidential general election.
C. Randal Mills, the 45-year-old CEO of California’s $3 billion stem cell research program, is a man who loves his milestones. A private pilot, he charts his course in the air from one specific point to the next. Three years ago, Mills brought that same sort of navigation to the state stem cell agency.
Examining a liquid nitrogen bank containing suspended stem cells. (Photo: Elena Pavolvich)You might say it is a case of “self-control” involving the test of a stem cell therapy for an infamous and terrible disease. Not self-control in the usual sense, but in the sense of controls during a clinical trial for a treatment prior to its release to the general public.
Examining a liquid nitrogen bank containing suspended stem cells. (Photo: Elena Pavolvich) Directors of California’s stem cell agency this morning approved financing terms for a proposed, $150 million, public-private company that the agency hopes will accelerate the creation of long-sought stem cell therapies. The plan to create a stem cell “powerhouse” is likely to be one of the landmark legacies of the state’s $3 billion research effort — for better or worse.
A depiction of human genetics. (Image: Crystal Image Photo, via Shutterstock)California’s stem cell agency has embarked on what is likely to be an exhaustive review of genetic alteration of human embryos with likely recommendations for changes in the $3 billion research effort. The 11-year-old agency plans to examine a host of issues ranging from inadvertent, inheritable changes in the human race to informed consent on the part of patients.